Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Protein kinase CK2 regulates B cell development and differentiationJournal of Immunology.  207:799-808. 2021
2021 Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson DiseaseNeurology, Neuroimmunology and Neuroinflammation.  8. 2021
2020 Protein kinase 2 (CK2) controls CD4+ T cell effector function in the pathogenesis of colitisMucosal Immunology.  13:788-798. 2020
2019 Novel biomanufacturing platform for large-scale and high-quality human T cells productionJournal of Biological Engineering.  13. 2019
2019 Deficiency of Socs3 leads to brain-targeted experimental autoimmune encephalomyelitis via enhanced neutrophil activation and ROS productionJCI insight.  4. 2019
2018 CK2 controls Th17 and regulatory T cell differentiation through inhibition of FoxO1Journal of Immunology.  201:383-392. 2018
2018 Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseasesClinical Immunology.  189:4-13. 2018
2018 Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson diseaseExperimental Neurology.  300:179-187. 2018
2017 The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac RejectionScientific Reports.  7. 2017
2017 Protein kinase CK2 controls the fate between Th17 cell and regulatory T cell differentiationJournal of Immunology.  198:4244-4254. 2017
2016 Erratum: SOCS3 deficiency promotes M1 macrophage polarization and inflammation (Journal of Immunology (2012) 189 (3439-3448))Journal of Immunology.  197:387-389. 2016
2016 Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration 2016
2016 Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of gliomaOncotarget.  7:20621-20635. 2016
2016 Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury 2016
2015 SOCS3 deficiency in myeloid cells promotes tumor development: Involvement of STAT3 activation and myeloid-derived suppressor cellsCancer Immunology Research.  3:727-740. 2015
2015 Opportunities for translation from the bench: Therapeutic intervention of the JAK/STAT pathway in neuroinflammatory diseasesCritical Reviews in Immunology.  35:505-527. 2015
2015 Preferential recruitment of neutrophils into the cerebellum and brainstem contributes to the atypical experimental autoimmune encephalomyelitis phenotypeJournal of Immunology.  195:841-852. 2015
2014 Tlr4 regulates IFN-γ and IL-17 production by both thymic and induced Foxp3+Tregsduring intestinal inflammationJournal of Leukocyte Biology.  96:895-905. 2014
2014 Perk-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammationMolecular and Cellular Biology.  34:3911-3925. 2014
2014 Therapeutic efficacy of suppressing the JAK/STAT pathway in multiple models of experimental autoimmune encephalomyelitisJournal of Immunology.  192:59-72. 2014
2013 ERK differentially regulates Th17- and Treg-cell development and contributes to the pathogenesis of colitisEuropean Journal of Immunology.  43:1716-1726. 2013
2013 AMP-activated protein kinase restricts IFN-γ signalingJournal of Immunology.  190:372-380. 2013
2012 SOCS3 deficiency promotes M1 macrophage polarization and inflammationJournal of Immunology.  189:3439-3448. 2012
2012 Regulation of CCL20 expression in astrocytes by IL-6 and IL-17Glia.  60:771-781. 2012
2012 Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation 2012
2012 ELISA methodology to quantify astrocyte production of cytokines/chemokines in vitroMethods in Molecular Biology.  814:235-249. 2012
2011 ACK2-dependent mechanism for activation of the JAK-STAT signaling pathwayBlood.  118:156-166. 2011
2011 Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 productionJournal of Immunology.  186:6313-6318. 2011
2010 Generation of mucosal dendritic cells from bone marrow reveals a critical role of retinoic acidJournal of Immunology.  185:5915-5925. 2010
2010 Suppressor of cytokine signaling 3 inhibits antiviral IFN-β signaling to enhance HIV-1 replication in macrophagesJournal of Immunology.  185:2393-2404. 2010
2010 IL-27 inhibits OSM-mediated TNF-α and iNOS gene expression in microgliaGlia.  58:1082-1093. 2010
2010 IL-17 enhancement of the IL-6 signaling cascade in astrocytesJournal of Immunology.  184:4898-4906. 2010
2010 Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune EncephalomyelitisImmunity.  32:414-425. 2010
2009 TGF-β promotes Th17 cell development through inhibition of SOCS3Journal of Immunology.  183:97-105. 2009
2008 Expression and functional significance of SOCS-1 and SOCS-3 in astrocytesJournal of Immunology.  181:3167-3176. 2008
2008 Molecular basis of oncostatin M-induced SOCS-3 expression in astrocytesGlia.  56:1250-1262. 2008
2008 The IFN-γ-induced transcriptional program of the CIITA gene is inhibited by statinsEuropean Journal of Immunology.  38:2325-2336. 2008
2007 The activation and up-regulation of co-stimulatory molecule CD40 of macrophage in LPS-induced acute lung injury model 2007
2007 Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microgliaJournal of Immunology.  179:5966-5976. 2007
2007 Simvastatin inhibits IFN-γ-induced CD40 gene expression by suppressing STAT-1αJournal of Leukocyte Biology.  82:436-447. 2007
2007 Type I interferons as anti-inflammatory mediators.Science's STKE : signal transduction knowledge environment.  2007. 2007
2006 IL-10 inhibits lipopolysaccharide-induced CD40 gene expression through induction of suppressor of cytokine signaling-3Journal of Immunology.  177:7761-7771. 2006
2006 IFN-β-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microgliaThe FASEB Journal.  20. 2006
2006 IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia.The FASEB Journal.  20:985-987. 2006
2005 LPS induces CD40 gene expression through the activation of NF-κB and STAT-1α in macrophages and microgliaBlood.  106:3114-3122. 2005
2004 Differential gene expression modulated by the cytoplasmic domain of FcγRIa (CD64) α-chainJournal of Immunology.  173:6211-6219. 2004
2004 Erratum: TRADD interacts with STAT1-α and influences interferon-γ signaling (Nature Immunology (2004) vol. 5 (199-207))Nature Immunology.  5:344. 2004
2004 TRADD interacts with STAT1-α and influences interferon-γ signalingNature Immunology.  5:199-207. 2004
2002 Diversity and duplicity: Human Fcγ receptors in host defense and autoimmunityImmunologic Research.  26:177-189. 2002
2002 The CY domain of the FcγRIa α-chain (CD64) alters γ-chain tyrosine-based signaling and phagocytosisJournal of Biological Chemistry.  277:41287-41293. 2002
2001 Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β: Critical role of STAT-1αJournal of Immunology.  167:5150-5159. 2001
1999 The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cellsJournal of Biological Chemistry.  274:29130-29137. 1999
1998 Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-α and IFN-γ1Journal of Immunology.  161:6664-6673. 1998
1997 TGF-β Suppresses IFN-γ Induction of Class II MHC Gene Expression by Inhibiting Class II Transactivator Messenger RNA ExpressionJournal of Immunology.  158:2065-2075. 1997

Research Overview

  • My research focus is mainly in the areas of neuroinflammation and immunology working together with Dr. Etty (Tika) Benveniste, Senior Vice Dean for Basic Sciences/Professor. My research projects are on understanding cytokine-induced signaling pathways and expression gene profiles in immune cells and brain glial cells, and in central nervous system (CNS) autoimmunity. I also investigate the function of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) and protein kinase CK2 pathways in the pathogenesis of animal models for Multiple Sclerosis (MS), Experimental Autoimmune Encephalomyelitis (EAE), Parkinson’s Disease (PD), Alzheimer’s disease (AD) and colitis.

    Specifically, I study the function of SOCS3, a negative regulator of the JAK/STAT pathway, in cells of the myeloid lineage in the pathogenesis of animal models for MS, EAE, PD, AD, colitis and tumorigenesis. My goal is to study the influence of the SOCS3 protein in activation of macrophages, microglia, neutrophils, and dendritic cells (DCs), and in the differentiation of Th1, Th17 and Treg cells, neuronal damage, myelin loss, and effects in the tumor microenvironment. As a PI or co-Investigator, I am involving in several previous and current university, National Multiple Sclerosis Society (NMSS) and NIH-funded grants. I have characterized the signaling pathways that lead to SOCS3 gene induction, and how the absence or presence of the SOCS3 protein influences the functionality of macrophages, microglia, T cells and astrocytes. My studies suggest that SOCS3 is a critical negative regulator for neuroinflammation in animal models of MS, PD and AD and tumor development.

    Another major research project is studying the influence of CK2 kinase in the disease development of MS patients, EAE models and colitis models. My focus is on the function of CK2 kinase in differentiation of CD4+ T cells, activation of DCs and activation and differentiation of B cells. My project titled “Function of Protein Kinase CK2 in CD4+ T Cells and Autoimmune Disease” was awarded by The National Multiple Sclerosis Society (NMSS, RG-1606-24794, 2017 - 2020) with Dr. Tika Benveniste and Dr. Laurie Harrington. The project titled “Uncovering the Role of Protein Kinase CK2 in B-cells in the Development of Neuroinflammation” will be submitted in October 05, 2020 to the NIH with collaborators Dr. Tika Benveniste, Dr. Laurie Harrington and Dr. Frances Lund.

    Regulation of the JAK/STAT pathway also serves as an approach to new therapeutics for neurodegenerative diseases. As a Co-Investigator, I have a close collaboration with Dr. David Standaert, Department of Neurology, and Dr. Tika Benveniste, on a P50 project (NS108675, $9.5 million) titled “Innate and Adaptive Immunity in Parkinson Disease”, which was recently funded by NINDS Morris K. Udall Centers. I play major roles on Project 1: Role of Innate Immune Cells in Human Parkinson Disease (PI: Standaert, David) and Project 2: Validating the JAK/STAT Pathway as a Novel Therapeutic Strategy in PD (PI: Benveniste, Etty). I contributed to the experimental designs, coordinated the collection and analysis of human subjects with the Clinical Core (PI: Talene Yacoubian), and performed experiments in animal models of PD with coordination of the Animal Core (PI: Laura Volpicelli-Daley). The collaborative project titled “JAK/STAT-mediated astrocyte reaction in AD” with Dr. Qin Wang will be submitted as R01 in February , 2020.

    I also collaborate with Dr. Yingzi Cong at the University of Texas Medical Branch at Galveston on studies in the regulation of the pathogenic function of CD4+ T cells in autoimmune diseases. My collaboration with Dr. Amit Gaggar (Department of Medicine, UAB) generated two recent (2016 and 2017) publications on lung injury models. The collaboration with Dr. Xiaoguang (Margaret) Liu in Department of Biomedical Engineering on tumor immunotherapy is ongoing, which resulted in a publication and an awarded grant titled “A targeted mitochondrial luminoptogenetic gene therapy to treat triple negative breast cancer”.
  • Investigator On

  • A Targeted Mitochondrial Luminoptogenetic Gene Therapy to Treat Triple Negative Breast Cancer  awarded by DOD - Department of Defense
  • Cytokine Production by Adaptive Immune Cells from Patients with Parkinson’s Disease: Response to Diverse Biological Stimuli  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease - Project 1: Role of Innate Immune Cells in Human Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease - Project 2  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease - Project 2: Validating the JAK/STAT Pathway as a Novel Therapeutic Strategy in PD  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease - Project 3: Role of Myeloid Cells in Human Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Innate and Adaptive Immunity in Parkinson Disease - Project 5: Innate and Adaptive Immunity in Lewy Body Dementia  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • The Role of the JAK/STAT Pathway in Human Parkinson's Disease  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • Therapeutic Intervention of the JAK/STAT Pathway for Neuroinflammation  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Therapeutic Intervention of the JAK/STAT Pathway for Treatment of Neuroinflammation  awarded by National Multiple Sclerosis Society ^
  • Full Name

  • Hongwei Qin